Pulmatrix, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2023. The unaudited filing was signed May 12, 2023. Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies using its iSPERSE platform; it had no product-sales revenue. Financial statement amounts below are in USD thousands, except per-share data.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $1,499 | $1,160 | +$339 (about 29%) |
| Research and development expense | $3,874 | $4,149 | -$275 |
| General and administrative expense | $2,210 | $1,974 | +$236 |
| Total operating expenses | $6,084 | $6,123 | -$39 |
| Operating loss | $(4,585) | $(4,963) | Loss narrowed $378 |
| Net loss | $(4,448) | $(4,973) | Loss narrowed $525 |
| Basic and diluted loss per share | $(1.22) | $(1.51) | |
| Net cash used in operating activities | $(4,928) | $(6,144) | Use decreased $1,216 |
Revenue was recognized under the PUR1900 collaboration with Cipla. One customer accounted for 100% of Q1 2023 revenue and accounts receivable. Interest income was $222, compared with $1 in Q1 2022; other expense was $85, compared with $11.
At March 31, 2023, cash and cash equivalents were $30,753; restricted cash totaled $1,625, giving cash, cash equivalents and restricted cash of $32,378. Total assets were $36,059, total liabilities $9,049, and stockholders’ equity $27,010. The filing reports no material debt balance. Management said existing cash was expected to fund operating expenses and capital needs for at least 12 months after filing, into Q4 2024, while cautioning that projections may prove inaccurate and additional capital will be needed.
Material changes and business developments
- Revenue increased by $339, primarily under the Cipla agreement. R&D expense fell $275: lower PUR3100 and PUR1800 spending was partly offset by increased PUR1900 spending. G&A increased $236, primarily due to legal and professional-services costs.
- Operating cash use improved year over year, but the company continued to incur losses and had an accumulated deficit of $277,924.
- PUR1900’s Phase 2b study began dosing patients in Q1 2023; topline results were anticipated in mid-2024. The agreement sets a June 30, 2023 milestone for 25% of enrolled patients to be dosed and a June 30, 2024 deadline for delivery of topline results to the joint steering committee.
- PUR3100 Phase 1 results reported before the filing indicated tolerability, lower incidence of nausea than IV DHE, no vomiting in the inhaled dose groups, and peak exposure in the target range at five minutes. The company planned an IND submission in mid-2023, but a Phase 2 study was dependent on financing or a partnership.
- PUR1800 Phase 1b results and chronic toxicology findings supported further development, but the company planned to seek a partner before advancing to Phase 2.
Outlook, risks and commitments
- Management expects significant expenses and operating losses for at least the next several years and anticipates needing additional capital through equity, debt, third-party funding, collaborations or strategic alliances. It was exploring financing or partnership arrangements for PUR3100.
- Research and development contracts represented approximately $5,200 of remaining commitments at quarter-end; the company expected $2,500 to be reimbursed under the Cipla agreement, and $4,400 of gross commitments were expected to be incurred within 12 months.
- The existing headquarters lease was due to expire August 31, 2023. A new Bedford facility was expected to commence in July 2023, with approximately $3,000 of company-funded improvements during construction, a $3,900 landlord tenant allowance, and base rent of about $100 per month over a ten-year noncancellable term.
- Principal risks include recurring losses and negative operating cash flow, adequacy and availability of financing, clinical and regulatory uncertainty, manufacturing and collaboration execution, intellectual-property protection, competition, macroeconomic conditions, and Nasdaq listing compliance. The company cited potential continuing effects of COVID-19, supply constraints, inflation, and geopolitical uncertainty.
- The company reported no material legal proceedings, no material off-balance-sheet arrangements, and effective disclosure controls; no material changes in internal control over financial reporting were reported.
Important facts for investors to verify
- Whether PUR1900 meets collaboration milestones and whether the Phase 2b trial remains on schedule for mid-2024 topline results.
- Available cash, actual quarterly cash burn, and the assumptions underlying management’s runway estimate into Q4 2024, including the new facility’s construction and lease costs.
- Progress on financing or partnership arrangements needed to initiate PUR3100 Phase 2 and advance PUR1800.
- Revenue concentration and dependence on the Cipla agreement: one customer generated all reported Q1 2023 revenue and receivables.
- Potential dilution: 3,652,285 common shares were outstanding at March 31, 2023; the filing also disclosed 418,948 options and 1,284,803 warrants outstanding, generally excluded from diluted loss per share as antidilutive.